Which bioprinting companies raised money?

This blog post has been written by the person who has mapped the bioprinting market in a clean and beautiful presentation

The bioprinting sector attracted over $203 million in disclosed funding across nine companies in 2024 and the first half of 2025.

Aspect Biosystems' $115 million Series B round dominated the funding landscape, while strategic partnerships with pharmaceutical giants like Novo Nordisk signal the sector's shift from research tools to therapeutic applications. Government initiatives through the European Innovation Council and NIH have provided crucial early-stage support, particularly for tissue engineering breakthroughs.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Which bioprinting startups raised funding in 2024 and 2025 so far, and how much did each raise?

Nine bioprinting companies secured funding ranging from $1.3 million to $115 million between January 2024 and June 2025.

Aspect Biosystems led with a $115 million Series B round in January 2025, followed by Nuclera's $75 million equity round in October 2024. UpNano raised €7 million ($7.5 million) in Series A funding, while Carcinotech secured £4.2 million ($5 million) for their tumor modeling platform.

The smaller rounds included 3D BioFibR's $3 million equity raise, Biological Lattice Industries' $1.8 million pre-seed, AMPLY Discovery's €1.5 million ($1.6 million) seed round, and VERIGRAFT's €1.2 million ($1.3 million) through European Innovation Council grants. EpiBone completed an undisclosed round led by Kendall Capital Partners.

These funding rounds span the entire development spectrum from pre-seed companies building foundational platforms to Series B companies preparing for clinical trials. The significant gap between Aspect Biosystems' round and others reflects the premium investors place on companies with clear therapeutic pathways.

Who are the top investors currently backing bioprinting companies, and which companies did they invest in?

Strategic pharmaceutical investors and government funding agencies dominate bioprinting investments, with traditional venture capital playing a supporting role.

Novo Nordisk emerged as the most prominent strategic investor through their partnership with Aspect Biosystems, focusing specifically on diabetes and obesity therapeutics. Radical Ventures previously led Aspect's Series A in 2020, establishing them as early believers in bioprinting's commercial potential.

Government entities provide crucial early-stage support, with the European Innovation Council funding VERIGRAFT's arterial graft development and the PRISM-LT tissue engineering consortium. The National Institutes of Health awarded $293,000 in diversity grants for vascular network bioprinting research at Penn State University.

Kendall Capital Partners led EpiBone's recent round, while Innovestor previously backed Brinter with €1.2 million in 2021. The investor landscape reveals a preference for specialized life science funds and strategic corporate investors over generalist venture capital firms.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Which bioprinting startup received the highest funding amount recently, and what are they working on?

Aspect Biosystems raised the largest round with $115 million in Series B funding in January 2025, developing AI-powered bioprinted tissue therapeutics.

The Canadian company uses their proprietary Lab-on-a-Printer™ platform to create implantable tissue therapeutics targeting metabolic disorders, specifically diabetes and obesity. Their microfluidic 3D bioprinting technology combines AI-guided biomaterial deposition with precision cell placement to manufacture allogeneic tissue products.

Aspect's strategic partnership with Novo Nordisk provides both financial backing and pharmaceutical expertise for their diabetes therapeutic pipeline. The company has progressed from providing research tools to developing clinical-grade implants, representing the bioprinting sector's maturation toward therapeutic applications.

Their technology addresses the challenge of creating vascularized tissue constructs that can survive implantation and integrate with patient biology. The substantial funding reflects investor confidence in bioprinting's transition from laboratory curiosity to commercial therapeutic platform.

What are the main bioprinting technologies or R&D breakthroughs that received funding in 2024 and 2025?

Five distinct technological approaches attracted significant investment, ranging from precision printing hardware to novel biomaterial production methods.

Which countries or regions are seeing the most bioprinting investment activity?

North America and Europe account for approximately 90% of disclosed bioprinting funding, with Asia representing an emerging but still limited presence.

North America leads with $193 million across three companies: Aspect Biosystems ($115M) and 3D BioFibR ($3M) in Canada, plus Nuclera ($75M) in the United States. Canada's strong showing reflects government support for biotechnology research and established bioprinting expertise.

Europe captured $15 million through five companies: AMPLY Discovery and Carcinotech in the United Kingdom, VERIGRAFT in Sweden, and UpNano in Austria. The European Innovation Council's Eurostars program provides crucial grant funding for early-stage companies developing tissue engineering applications.

Asia remains underrepresented in major funding rounds, though companies like Pandorum in India and SPEBIO in South Korea are building early-stage capabilities. Government initiatives in Singapore, Japan, and South Korea suggest increased activity in the next funding cycle.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Are any major players from pharma, medtech, or 3D printing industries investing in or acquiring bioprinting companies?

Pharmaceutical companies are actively engaging through strategic partnerships rather than outright acquisitions, while traditional 3D printing companies remain notably absent from major deals.

Novo Nordisk represents the most significant pharmaceutical engagement through their strategic partnership with Aspect Biosystems, combining financial investment with access to diabetes and obesity therapeutic expertise. This partnership model allows pharmaceutical companies to access bioprinting capabilities without the risks of early-stage technology development.

The European Innovation Council operates as a public-private hybrid, funding tissue engineering projects like VERIGRAFT's arterial grafts and the PRISM-LT consortium. These initiatives bridge government research funding with commercial applications, reducing risk for private investors.

Notably absent are major 3D printing hardware manufacturers like Stratasys, 3D Systems, or HP, suggesting they view bioprinting as too specialized or early-stage for their traditional manufacturing focus. Medtech giants also remain on the sidelines, likely waiting for clearer regulatory pathways and clinical validation.

If you want to build or invest on this market, you can download our latest market pitch deck here

What are the terms or stages of the recent funding rounds—seed, Series A, strategic partnerships, or government grants?

The funding distribution shows a mature ecosystem with companies across all development stages, from pre-seed hardware development to Series B therapeutic applications.

• Series B (1 round): Aspect Biosystems' $115 million represents the sector's most advanced funding stage, reflecting their progression toward clinical applications and strategic pharmaceutical partnerships.
• Series A (1 round): UpNano's €7 million Series A focuses on scaling their two-photon polymerization printer manufacturing for precision bioprinting applications.
• Seed/Pre-seed (4 rounds): Early-stage companies including 3D BioFibR ($3M), Biological Lattice ($1.8M), AMPLY Discovery ($1.6M), and Carcinotech ($5M) are building foundational platforms.
• Government grants (3 initiatives): VERIGRAFT (€1.2M Eurostars), PRISM-LT (€2.3M EIC), and NIH vascularization research ($293K) provide crucial early-stage support.
• Undisclosed equity (2 rounds): Nuclera ($75M) and EpiBone (undisclosed) completed significant rounds without revealing specific terms or stages.

Which companies received repeat funding rounds, and what milestones did they achieve between rounds?

Two companies demonstrate clear progression through multiple funding cycles, showing measurable advancement in their technology platforms and commercial applications.

3D BioFibR completed three funding rounds since 2020: initial seed of $550,000, follow-on seed of $3.52 million in July 2023, and recent $3 million equity round in June 2025. Between rounds, they scaled their automated dry-spinning platform for collagen and spider silk fiber production, moving from laboratory prototypes to commercial-ready biopolymer manufacturing systems.

Aspect Biosystems raised $20 million in Series A funding in 2020 led by Radical Ventures, then completed their $115 million Series B in January 2025. During this five-year period, they advanced from providing bioprinting research tools to developing therapeutic tissue implants, secured their strategic partnership with Novo Nordisk, and moved toward clinical applications for diabetes and obesity treatments.

The progression of these companies illustrates the typical bioprinting development timeline: initial funding supports platform development, follow-on rounds enable scaling and application development, and later-stage funding prepares for clinical validation and commercialization.

Are there any government-backed or public-private initiatives that funded bioprinting startups recently?

Government and public-private funding provides essential early-stage support, particularly for tissue engineering applications that require long development timelines before commercial validation.

The European Innovation Council's Eurostars program awarded €1.2 million to VERIGRAFT in February 2025 for developing personalized arterial grafts using their PREPPER technology. The same program provided €2.3 million to the PRISM-LT consortium in 2024 for developing symbiotic bioinks that support living tissue development.

The National Institutes of Health awarded a $293,000 diversity grant supplement to Pennsylvania State University in December 2023, supporting vascular network bioprinting research as part of a larger $3 million NIH award. This funding specifically targets the critical challenge of creating blood vessel networks within bioprinted tissues.

These government initiatives focus on fundamental research challenges that private investors consider too risky or long-term. The grants serve as crucial bridge funding that validates technologies and reduces risk for subsequent private investment rounds.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

If you need to-the-point data on this market, you can download our latest market pitch deck here

How much total capital was raised across the bioprinting sector in 2024 and year-to-date 2025?

The bioprinting sector attracted at least $203 million in disclosed equity funding across nine companies during the 2024-H1 2025 period, plus approximately €3.5 million in government grants.

The equity funding breaks down across different stages: one Series B round ($115M), one Series A round ($7.5M), four seed/pre-seed rounds ($13.4M total), and three undisclosed equity rounds ($67M disclosed, with EpiBone's amount unreported). Government grants contributed an additional €3.5 million ($3.8M) plus $293,000 in NIH funding.

This figure represents only publicly disclosed rounds and likely underestimates total sector activity. Many early-stage bioprinting companies secure private funding without public announcement, and strategic partnerships often involve undisclosed financial terms beyond the headline investment amounts.

The concentration of funding in larger rounds reflects the sector's maturation, with 82% of disclosed funding going to just two companies (Aspect Biosystems and Nuclera) that have moved beyond platform development toward specific therapeutic applications.

Which use cases—such as tissue engineering, organ-on-chip, or regenerative medicine—are attracting the most funding?

Regenerative medicine applications attracted the largest funding share at $118.3 million, followed by precision bioprinting hardware at $82.5 million and tissue engineering platforms at $4.8 million.

What trends or upcoming developments are investors expecting in the bioprinting sector in 2026?

Investors anticipate 2026 will mark bioprinting's transition from research platform to clinical reality, with the first biotech-approved bioprinted implants entering human trials.

Therapeutic translation represents the primary investment thesis, with large Series B rounds signaling investor confidence in moving beyond laboratory models to clinical-grade implants. The success of companies like Aspect Biosystems in securing pharmaceutical partnerships validates the commercial potential of bioprinted therapeutics.

Platform technology consolidation will accelerate through partnerships between deep-tech venture capital firms and pharmaceutical companies, similar to the Novo Nordisk-Aspect Biosystems collaboration. These partnerships provide both financial resources and regulatory expertise necessary for clinical development.

Government funding through programs like Eurostars and NIH grants will continue de-risking early-stage science and bridging gaps to private investment. Integrated biofabrication companies offering combined hardware-software-bioink solutions will gain traction as customers seek end-to-end platforms rather than individual components.

Regional diversification will expand beyond North America and Europe, with Asia-Pacific biotech hubs in India, South Korea, and Singapore likely seeing increased seed-stage deals as local governments increase R&D support for biotechnology applications.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Conclusion

Sources

1. 3D Print - Angel Investors in 3D Printing
2. EU Startups - VERIGRAFT Funding
3. Aspect Biosystems - Series A Announcement
4. Brinter - Seed Funding Announcement
5. 3D Print - Bioprinting Investment Milestones
6. VentureRadar - Bioprinting Funding
7. BusinessWire
8. FinSMEs